hotspot -WSS

hotspot

author：comprehensive 2025-10-02 11:09:33 - browse：81149

A display of TVs against an orange background. -- health policy coverage from STAT — Adobe

WASHINGTON — Government regulators may soon decide whether to crack down on distracting visuals in television drug commercials or require subtitles about side effects, a regulation that’s been 13 years in the making.

White House budget experts are reviewing changes to the regulation of broadcast drug advertisements that the Food and Drug Administration proposed in 2010, according to the Office of Management and Budget website. That proposal aimed to make commercials present drug risks in a manner that consumers notice and understand.

Drug ads have long been controversial. Aside from New Zealand, the United States is the only country that allows drug makers to advertise to consumers. Critics of drug ads say they pose consumer safety concerns by bombarding the public with promotions that distract viewers from potential side effects. Drug companies say commercials spark conversations between patients and doctors that promote clinically beneficial prescribing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Merck, Johnson & Johnson CEOs will testify on high drug prices

WSS

Zyn nicotine pouches become unlikely player in latest culture war

Wegovy leads to weight loss. Can it treat depression, too?

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Merck, Johnson & Johnson CEOs will testify on high drug prices

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

STAT Summit: GSK CEO on pharma giant's new direction

focus

hotspot

Wikipedia

Psychedelics group wrestles with new pharma identity

Eli Lilly expects to double planned employment in Boston center

Malaria cases in Florida and Texas: Here’s what you need to know

Boston competes with Raleigh

ChatGPT in medicine: STAT answers readers' burning questions

STAT Summit: GSK CEO on pharma giant's new direction

New air purifier tech could be key to improving indoor air quality

CEOs share strategies for surviving biotech slump

What does generative AI mean for health care? We asked experts

The explosion of genetic testing requires a new approach

explore

Biogen walks away from Aduhelm, years after polarizing approval

Hospital price transparency does save money, advocate argues

Impact of Dobbs ruling felt at reproductive medicine meeting

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

2023 STAT Wunderkinds: get to know the winners

Venture capital firm's plans to take over Akron hospital face hurdles

leisure time

leisure time

explore

leisure time